August 20, 2015
Roche’s anti-PD-L1 antibody atezolizumab has met its primary endpoint and tumor reduction (overall response rate) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) in the multinational PII BIRCH study including Japan, the Swiss giant has said...read more